Pixelgen closes $15.5M Series B to scale cell architecture platform
What's the deal? Stockholm-based Pixelgen Technologies has closed an oversubscribed $15.5 million (about SEK 150 million) Series B, announced in August 2026. New investor Flat CapitalDealroom has a profile for this one. Try Dealroom → led the round, with existing backers Industrifonden and Navigare VenturesDealroom has a profile for this one. Try Dealroom → returning.
Where the money goes. The company will use the financing to accelerate global commercialisation of its Proxiome Kit, expand its team and product portfolio, and broaden its data analysis and visualisation software.
Why it matters. Pixelgen's platform maps molecular cell architecture at nanoscale resolution, showing how proteins are organised, clustered and localised on individual cell surfaces. The company says the technology could support research into cancer, immunology and autoimmune disease.
Leadership. CEO and co-founder Simon FredrikssonDealroom has a profile for this one. Try Dealroom → said the funding will help bring molecular cell architecture to more researchers. Ramon FelcianoDealroom has a profile for this one. Try Dealroom → and Flat Capital CEO Rickard El Tarzi are joining Pixelgen's board. Felciano founded Ingenuity Systems, later acquired by QIAGENDealroom has a profile for this one. Try Dealroom →.
Image credit: Pixelgen
Read more: PR Newswire
